Sequence information
DRAVP ID DRAVPc022
Name Albinterferon Alfa-2B
Sequence Not available
Molecular Formula C3796H5937N1015O1143S50
Condition/Disease Chronic HCV infection, Chronic HBV infection
Group Phase Ⅲ clinical trial
Type Protein
Description Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.
Active sequence/Structure
External Links
DrugBank Accession Number DB05396
Pubchem ID 347910117
CHEMBL ID CHEMBL2107842
UNII 4DVS4AG4DF
CAS 472960-22-8
Reference 12388634
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT00097435 | A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C | Hepatitis C Virus (HCV) Infection Treatment | Completed | Phase 2 | Human Genome Sciences Inc. |
| NCT00656006 | A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 | Chronic Hepatitis C Virus (HCV) Infection Treatment | Completed | Phase 2 | Human Genome Sciences Inc. |
| NCT00115908 | A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 | Chronic Hepatitis C Virus (HCV) Infection Treatment | Completed | Phase 2 | Human Genome Sciences Inc. |
